Russian mRNA skin cancer vaccine shows six-month treatment cycle, researchers say
Russian medical researchers have outlined the treatment duration and protocol for a newly developed mRNA-based vaccine designed to target skin cancer, marking a further step in the country’s experimental cancer immunotherapy programs.
According to the National Medical Research Radiological Centre, the full therapeutic cycle of the personalized mRNA vaccine extends over six months. The treatment involves a structured injection schedule beginning on days one, eight, and fifteen, followed by gradually increased intervals, eventually reaching one dose every 21 days.
Medical experts indicate that patients may receive up to ten injections in total, often administered alongside immunotherapy to enhance the body’s immune response against cancer cells.
Andrey Kaprin, chief oncologist at the Russian Ministry of Health, noted that skin cancer is most frequently diagnosed in elderly patients, typically between the ages of 70 and 75. However, he stressed that no age group is completely immune, as the disease can also affect the skin, eye surface, oral cavity, and intestinal mucosa.
The development follows earlier experimental use of a personalized mRNA cancer vaccine known as “NeoOncovac,” which was tested on a skin cancer patient in collaboration with the Gamaleya National Research Center for Epidemiology and Microbiology.
Researchers say the approach is part of a broader effort to develop individualized cancer therapies that stimulate targeted immune responses, although further clinical evaluation is required to assess long-term effectiveness and safety.
-
12:00
-
11:45
-
11:15
-
11:00
-
10:45
-
10:30
-
10:15
-
10:00
-
10:00
-
09:45
-
09:30
-
09:15
-
09:00
-
09:00
-
08:45
-
08:27
-
00:10
-
22:30
-
22:00
-
21:30
-
21:00
-
20:30
-
20:00
-
19:30
-
19:00
-
18:30
-
18:00
-
17:30
-
17:00
-
16:30
-
16:03
-
16:00
-
15:30
-
15:16
-
15:08
-
15:00
-
14:30
-
14:00
-
13:30
-
13:00
-
12:45
-
12:30
-
12:15
